Madrid

• A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria … Ended
  2023-506238-61-00 5 2024-05-10 Phenylketonuria
• A First in Human open label study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-Tumor Activi … Ended
  2023-508386-32-00 1 2024-05-10 Hematologic tumors
• A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Ended
  2023-503223-26-00 9 2024-05-07 Advanced Solid Tumors Harboring a KRASG12C Mutation
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject … Ended
  2023-505842-24-00 5 2024-05-07 Moderate to Severe Plaque Psoriasis
• Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral do … Ended
  2023-506938-68-00 2 2024-05-03 Alzheimer's disease
• First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer Ended
  2023-504012-16-00 7 2024-04-29 Unresectable Locally Advanced or Metastatic Cancer
• A clinical research study to learn if baxdrostat works at reducing ambulatory blood pressure and is safe for people with high blood pressure … Ended
  2023-507640-36-00 5 2024-04-29 Resistant hypertension (rHTN) defined as blood pressure that remains h
• MYK-224 in Heart Failure with Preserved Ejection Fraction (HFpEF) Ended
  2023-505919-21-00 4 2024-04-25 Heart failure with preserved ejection fraction (HFpEF)
• Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) Ended
  2022-502899-23-00 5 2024-04-23 Hepatic Encephalopathy (OHE)
• Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer Ended
  2023-504630-22-00 7 2024-04-19 Non-Small Cell Lung Cancer
• A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended
  2023-505857-42-00 4 2024-04-19 Chronic Kidney Disease, Type 2 diabetes
• A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies Ended
  2023-508209-25-00 1 2024-04-19 B-Cell Non-Hodgkin’s Lymphoma (B-NHL)
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• Trial to assess the safety and preliminary efficacy of GEN1055 on malignant solid tumors as monotherapy and as combination therapy. Ended
  2023-507049-28-00 7 2024-04-16 Malignant Solid Tumors
• Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended
  2023-505803-22-00 4 2024-04-15 Hidradenitis
• A Phase 2 Trial of BDC-1001 as Single Agent and in Combination with Pertuzumab in Subjects with Human Epidermal Growth Factor Receptor 2–Pos … Ended
  2023-506038-65-00 4 2024-04-15 HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CA
• A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended
  2023-507217-10-00 5 2024-04-12 Thyroid eye disease
• Comparison of three short rifamycin-based regimens to treat latent tuberculosis in patients with end-stage kidney disease. Ended
  2023-506432-32-00 6 2024-04-11 Latent tuberculosis infection in patients with end-stage kidney diseas
• A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Ended
  2023-503693-20-01 5 2024-04-10 Severe eosinophilic asthma
• RANDOMISED, CROSSOVER, SIMPLE-BLINDED, BIOEQUIVALENCE CLINICAL TRIAL OF ALMOTRIPTAN 12.5 MG ORODISPERSIBLE TABLETS VERSUS ALMOTRIPTAN 12.5 M … Ended
  2023-508747-49-00 2 2024-04-10 Antimigraine
• A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi … Ended
  2022-501421-20-00 5 2024-04-09 Gout with hyperuricemia
• PH2a, VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living with HIV-1 Ended
  2023-507173-18-00 4 2024-04-09 HIV Infections
• A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid Tumors Ended
  2022-500823-61-00 7 2024-04-08 Advanced Solid Tumours

Showing 2,785–2,808 of 3,550 trials